Personality Disorders
Personality Disorders (DSM-5-TR)
Enduring patterns of inner experience and behavior that deviate from cultural expectations, are pervasive and inflexible, and cause distress or impairment. BPD is best-studied; DBT, MBT, TFP, and Schema Therapy have strongest evidence. Treatment typically longer-term.
Prevalence: ~10% general population; ~40-60% of clinical populations
Clinical Picture
Personality disorders — particularly borderline, narcissistic, and avoidant — represent some of the most challenging and most rewarding clinical work. These are not acute symptoms that developed in response to a specific stressor but enduring patterns of experiencing self and others that developed early and have become the water the client swims in. The diagnostic label itself is controversial: 'personality disorder' can pathologize adaptations that made sense in context, and the 'Cluster B' stigma in clinical settings is well-documented. The most clinically useful framing may be characterological patterns that cause suffering and that the client wants to understand and potentially change.
Treatment Considerations
DBT is the most extensively researched treatment for borderline personality disorder specifically, with strong evidence for reducing self-harm, suicidal behavior, and treatment dropout. Schema Therapy has growing evidence for BPD and other personality disorders, particularly for the chronic emptiness and identity disturbance dimensions. Transference-Focused Psychotherapy (TFP) and Mentalization-Based Treatment (MBT) approach personality disorders through the psychoanalytic lens of object relations and reflective functioning. For narcissistic presentations, Schema Therapy and psychoanalytic approaches tend to have more developed clinical frameworks than CBT-based models.
24 Therapeutic Approaches
Sorted by evidence tier: guideline-recommended first, then RCT-supported, then emerging/limited evidence.
Related Clinical Vignettes
Sources & References
Prevalence data from NIMH, WHO, and DSM-5-TR field trial publications. Evidence tiers reflect guideline status (APA, NICE, VA/DoD, WHO) and meta-analytic findings as of early 2025. Individual modality citations are listed on each modality page. Full bibliography available on the Sources page.